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There are 23 pairs of human chromosomes. Any 
chromosome number that is not an exact multiple 
of the haploid number (i.e., n = 23 in humans) indi-
cates aneuploidy. The common forms of aneuploidy 
in humans are trisomy (the presence of an extra 
chromosome) and monosomy (the absence of a sin-
gle chromosome). There are only three, well-defined 
non-mosaic chromosome disorders compatible with 
postnatal survival in which there is trisomy for an 
entire autosome: Trisomy 21 (Down syndrome, the 
most common), trisomy 18 (Edwards syndrome, the 
second most common), and the rather rare, trisomy 
13 (Patau syndrome).1−3 Each of these autosomal 
trisomies is associated with growth and mental re-
tardation, and multiple congenital anomalies. The 
clinical features characteristic of any one trisomic 
state are determined by the extra dosage of the 
particular genes on the additional chromosome. 
Trisomies may also be present in mosaic form, with 
variable, but usually somewhat milder, expression 
or longer survival. Most autosomal trisomy syndromes 
are associated with increased maternal age, and 
the extra chromosome usually arises from non-
disjunction occurring at maternal meiosis I.
Prenatal ultrasound can detect many abnormal-
ities. Karyotyping analysis following chorionic villus 
sampling or amniocentesis, or blood tests after 
birth, can confirm the diagnosis. Imaging studies such 
as ultrasound or magnetic resonance imaging of 
the heart and abdomen can also detect fetal ab-
normalities. Medical care for individuals with au-
tosomal trisomies is supportive, and focuses on 
providing nutrition, treating infections, and manag-
ing organ abnormalities. Most mortality in patients 
with Down syndrome occurs during the first year of 
life; the 1-year survival rate is 93.6%, indicating that 
the life expectancy in patients with trisomy 21 is 
much longer than generally believed.1 However, 
infants with trisomy 18 or 13 only have a 5−10% 
chance of surviving to age 1 year, probably because 
of the complex medical problems, including multi-
ple organ defects and overwhelming infections.2,4−7 
In the mean time, major medical or aggressive sur-
gical interventions are often withheld from these 
children.
Many factors have the potential to affect survival 
rates. In this issue of the journal, Hsiao et al8 re-
port on their analysis of detailed data from 31 live-
born babies with Edwards syndrome. Early diagnosis, 
changes in medical management, and the family’s 
attitude are considered to be the major factors in-
fluencing survival. A recent report regarding the 
survival and natural history of trisomy 18 by Lin et al2 
showed that the implementation of a National Health 
Insurance (NHI) program also facilitated longer 
survival in these patients. The degree to which es-
sential organs are affected at birth and the clinical 
course differ considerably. Hsu and Hou3 found that 
most trisomy 13 patients were born to younger 
mothers who did not undergo amniocentesis, be-
cause no major anomalies except for cleft lip/pal-
ate were found on prenatal sonograms. The median 
survival time in their series was longer than that 
previously reported. A less severe course of auto-
somal trisomy syndrome can be caused by a partial 
trisomy, due to a deletion of the extra chromo-
some 18, or somatic mosaicism with a trisomic
and a normal cell-line in the same patient. However, 
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different outcomes in both clinical spectrum and
survival have been reported in patients with tri-
somic mosaicism.3,9 Unlike trisomies 21 and 13, the 
preponderance of females with trisomy 18 among 
live-born infants (sex ratio, 0.63) compared with 
prenatally diagnosed fetuses (sex ratio, 0.90) indi-
cates prenatal selection against males with trisomy 
18 after the time of amniocentesis,10 or preferential 
survival of female fetuses.
Trisomy 18 and trisomy 13 are associated with se-
rious and/or fatal birth defects, many of which re-
quire surgical correction during the neonatal period. 
Difficult medical and ethical issues arise over 
whether or not to institute treatment when a new-
born infant with autosomal trisomies has a life-
threatening anomaly. Improved survival through 
the advent of neonatal intensive care and NHI treat-
ment allow clinicians to offer the best information 
on treatment options to the families of these pa-
tients.2,5,8 The chances of long-term survival can 
be increased by different expressivity after prena-
tal selection, as well as by cytogenetic mosaicism. 
Unknown genetic factors and various environmen-
tal effects are likely to be involved. In conclusion, 
the increasing utilization of prenatal diagnostic tools, 
earlier postnatal diagnosis, and advances in medi-
cal care, mean that the clinical presentations and 
survival patterns of autosomal trisomy syndromes 
have changed in recent decades. Accurate prognos-
tic information, including the possibility of long-
term survival, is crucial for allowing families to 
make the most appropriate decisions about further 
management.
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